

FDA medical reviewers ask members of the Peripheral and Central Nervous System Drugs Advisory Committee to confirm the benefits and risks of Eisai/Biogen’s Leqembi in treating early Alzheimer’s disease.

Human Drugs
PMI ‘Major Change’ in Drug Labeling: Attorneys
Five Hogan Lovells attorneys explain how an FDA proposal to require Patient Medication Information would represent a significant change in drug labeling.